Rigel Pharmaceuticals, Inc.
RIGL
$41.50
-$0.49-1.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 420.82% | -20.19% | 15.46% | 1,305.92% | 87.51% |
| Total Depreciation and Amortization | 0.50% | 0.00% | -1.15% | -0.33% | 53.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,279.16% | 78.58% | -31.23% | 7.72% | -51.94% |
| Change in Net Operating Assets | 145.23% | -631.77% | -136.05% | 469.39% | 21.24% |
| Cash from Operations | 3,519.60% | -106.16% | -33.10% | 7,078.48% | 106.02% |
| Capital Expenditure | -- | -- | -160.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 176.92% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -120.58% | 3.72% | -389.49% | -65.36% | 3,391.69% |
| Cash from Investing | -120.58% | 3.32% | -387.06% | -65.21% | 3,391.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -13.64% | -66.96% | 827.22% | -37.30% | 183.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -896.02% | 61.40% |
| Cash from Financing | -13.64% | -66.96% | 114.89% | -1,208.78% | 70.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 170.06% | -316.88% | -67.68% | 49.24% | 245.30% |